U.S., June 10 -- ClinicalTrials.gov registry received information related to the study (NCT07635056) titled 'Haploidentical Donor Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Neuroblastoma' on May 28.
Brief Summary: The goal of this study is to demonstrate that cytokine-induced memory-like natural killer cells (CIML-NK cells) can be generated from donor cells and infused safely into patients with relapsed or refractory neuroblastoma during dinutuximab-based therapy.
Study Start Date: July, 2026
Study Type: INTERVENTIONAL
Condition:
Neuroblastoma
Intervention:
BIOLOGICAL: CIML-NK Cells
The investigational cell product is a cytokine-induced memory-like natural killer cell preparation, derived f...